In today’s ACT Brief, we explore how real-world data can improve protocol design and feasibility, highlight new findings from ...
Understand how combining proprietary and real-world datasets with tokenization enables accurate protocol matching while ...
In contrast, by utilizing technology-driven tools more effectively, we can drive efficiencies, improve communication, and ...
Gain insight into how principal investigator scarcity, frequent protocol amendments, and uneven site performance undermine ...
Learn how incorporating real-world data at study design can improve feasibility, reduce amendments, and align eligibility ...
In today’s ACT Brief, we highlight new insights on recruitment bottlenecks from Citeline’s Matt Holms, UCB’s first-in-class ...
Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...
In today’s ACT Brief, we highlight new insights from TransCelerate on streamlining clinical data to reduce burden, explore ...
Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...
Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...
Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...
Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback